Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care

Abstract

This eleventh review of global reporting of ADRs for drugs used to treat COVID-19 is as before mainly descriptive in nature. It includes reviews for the drugs that were initially included in WHO Solidarity trial to find an effective COVID-19 treatment and other drugs used for a COVID-19 indication where the number of reports in VigiBase exceeds 100. Regarding remdesivir, a major increase in reports was seen in this review. Notable numbers of reports for several non-labelled ADR terms have been shared within the system, described in the remdesivir section of the document. Concerning the other drugs reviewed, ADR-patterns are consistent with those described in earlier reports and mostly within the labelling for the respective drugs. Reports have been shared from all WHO regions, with the largest number now originating in the WHO region of the Americas with 45% of the shared reports (Table 2). WHO has announced the discontinuation of the hydroxychloroquine (HCQ) and lopinavir;ritonavir arms of the Solidarity trial as per the recommendation from the international steering committee 1 . The decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir;ritonavir in nonhospitalized patients or as pre-or post-exposure prophylaxis for COVID-19.

Evaluation of Remdesivir in Liver Functions Covid-19 Patients At Bhayangkara H.S Samsoeri Mertojoso Hospital Surabaya

“…In patient code 84, there was an increase in liver function parameters after remdesivir administration, even though it was supplemented with a hepatoprotector. Elevated liver biochemistry is mostly associated with severe and critical Covid-19 conditions for multifactorial reasons, such as drug-induced liver function abnormalities, liver involvement in critical illness and hypoxic disorders [14]. Severe cases are more likely to have severe liver injury when compared to mild cases [13], [15], [16].…”

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

“…Finally, the spectrum of COVID-19related manifestations turned out to be associated with a broad range of systemic symptoms, e.g., neurological and dermatological syndromes, myocardial dysfunction, hyperglycemia, disorders of the gastrointestinal tract and acute kidney failure [9][10][11][12][13][14]. Concomitantly, a lot of observations also started to suggest an existing relationship between SARS-CoV-2 and chronic liver diseases (CLDs), indicating hepatic manifestations of the infection and the exacerbation of existing liver pathologies in the case of COVID-19 [15][16][17][18][19][20][21]. Further, preexisting systemic disorders were also proved to modify the natural history of COVID-19, usually exacerbating its course and resulting in a more complex presentation of the infection.…”